Extraosseous Ewing sarcoma in children and adolescents: A retrospective series from a referral pediatric oncology center

2021 ◽  
Author(s):  
Virginia Livellara ◽  
Luca Bergamaschi ◽  
Nadia Puma ◽  
Stefano Chiaravalli ◽  
Marta Podda ◽  
...  
2018 ◽  
Vol 27 (1) ◽  
pp. 8-8 ◽  
Author(s):  
Ilan Kent ◽  
Evgeny Edelstein ◽  
Olga Levin ◽  
Yaron Wiener

.


2011 ◽  
Vol 57 (1) ◽  
pp. 69-75 ◽  
Author(s):  
Jaume Mora ◽  
Carmen de Torres ◽  
Andreu Parareda ◽  
Ferran Torner ◽  
Patricia Galván ◽  
...  

Author(s):  
Arvind Sathyamurthy ◽  
Ashish Singh ◽  
Tarun Jose ◽  
Patricia Sebastian ◽  
Rajesh Balakrishnan ◽  
...  

Abstract Aim: To analyse the presentation, diagnosis and patterns of care of extraosseous Ewing sarcoma treated at our institution between 2008 and 2018. Methods: Electronic medical records of extraosseous Ewing sarcoma patients treated at our institution between January 2008 and April 2018 were reviewed. Kaplan–Meier curves were plotted to assess the overall and disease-free survival with 95% confidence intervals. A univariate analysis was carried out to assess the impact of variables such as surgical excision, completeness of surgery, completeness of chemotherapy and addition of radiation therapy on the survivorship. Results: The records of 65 patients treated at our institution were available for review. The mean age was 26·4 years. The most frequent sites of extraosseous Ewing tumour were kidney—9/65 (13·8%) and brain—10/65 (15·4%). Sixteen (24·6%) patients presented with inoperable/metastatic disease at diagnosis. The other 49 (75·4%) had localised disease at presentation. The median overall survival of the 49 non-metastatic patients was 46 months, and the disease-free survival was 45 months. Conclusion: Extraosseous Ewing sarcoma is a rare and aggressive tumour diagnosed by molecular techniques. Multi-modality treatment including surgical resection with wide margins, adjuvant radiation when indicated and completion of systemic chemotherapy results in optimum outcomes.


2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S274-S274
Author(s):  
Ruba Barbar ◽  
Hana Hakim ◽  
Patricia Flynn ◽  
Aditya H Gaur ◽  
Darenda Wright ◽  
...  

Abstract Background Central venous catheters (CVCs) are important for healthcare delivery in pediatric oncology patients. It is common to repair CVC breakage to prevent replacement. Existing evidence regarding the association between CVC repair and bloodstream infections (BSI) is limited in the general pediatric population and lacking in pediatric oncology patients. We aim at evaluating whether repairing broken CVCs is associated with an increased risk for subsequent BSI in a pediatric oncology center. Methods This is a retrospective case-crossover study of pediatric oncology patients with broken CVCs that underwent repair between July 2015 and June 2017. The incidence and characteristics of BSI in the 30-day pre-repair period were compared with those in the 30-day post-repair period. Wilcoxon-Mann–Whitney and Fisher’s Exact tests were used for comparison of continuous and categorical variables, respectively. Univariate logistic regression was used to identify potential risk factors for BSI post CVC repair. Multiple breakages of the same CVC, and BSIs in overlapping observation periods of consecutive breakages are assumed independent. Results Sixty-four patients had 99 episodes of CVC breakage/repair in 68 CVCs. Median age (range) at repair was 2.5 (0.15–17.6) years. 48% of CVC breakages occurred in patients with solid tumors, 24% in HSCT recipients, and 19% in patients with leukemia. Only 25% of patients had neutropenia at repair and 14% had CVC occlusion 72 hours prior to breakage. All CVCs were made of silicone and 88% were double lumen external tunneled. First CVC breakage occurred at a median (range) of 130 (2–718) days since insertion, and CVCs were removed at a median (range) of 72.5 (3–753) days from the last repair. End of treatment was the most common cause (43%) for removal. The post-repair incidence of BSI was 4.5 per 1000 line-days compared with a pre-repair incidence of 4.3 (RR= 0.95, 95% CI 0.44, 2.18). There is no statistical difference between the characteristics of the pre-repair and post-repair BSI (Table 1). Figure 1 shows the organisms causing BSI before and after CVC repair. None of the evaluated variables was identified as a significant risk factor for BSI 30 days after CVC repair (Table 2). Conclusion Repair of CVC in pediatric oncology patients was not associated with increased risk of BSI. Disclosures All authors: No reported disclosures.


2013 ◽  
Vol 29 (12) ◽  
pp. 1303-1309 ◽  
Author(s):  
Sajid S. Qureshi ◽  
Siddharth Laskar ◽  
Seema Kembhavi ◽  
Sanjay Talole ◽  
Girish Chinnaswamy ◽  
...  

2020 ◽  
pp. 1-11
Author(s):  
Daphné Lemieux-Sarrasin ◽  
Marie-Claude Pelland-Marcotte ◽  
David Simonyan ◽  
Émilie Martineau ◽  
Barbara Desbiens ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document